Status
Conditions
Treatments
About
The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
Full description
In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Patients must have:
Prior Medication:
Allowed:
AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Patients with the following prior conditions are excluded:
History of clinically relevant pancreatitis or hepatitis within the past 6 months.
Required:
Antiretroviral therapy with either single or double reverse transcriptase inhibitors.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal